Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00038428

Enrollment

Registered

2002-05-31

Start date

2001-06-30

Completion date

2005-07-31

Last updated

2011-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Neoplasms

Brief summary

The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every week in the treatment of patients with advanced ovarian cancer that is resistant to platinum-based chemotherapy.

Interventions

DRUGTLK286

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histologic diagnosis of ovarian cancer * Recurrent or persistent disease following primary therapy * Measurable disease * Prior treatment with at least one but no more than three prior chemotherapy regimens * Resistant or refractory to platinum-based chemotherapy * At least 18 years of age * Good performance status (ECOG 0 to 1) * Adequate liver, renal and bone marrow function

Exclusion criteria

* Pregnant or currently breast feeding * Treatment with chemotherapy or immunotherapy within four weeks * Prior radiation to the whole pelvis

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026